Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Insider David Krempa Sells 10,223 Shares

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) insider David Krempa sold 10,223 shares of the company’s stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $14.73, for a total value of $150,584.79. Following the completion of the transaction, the insider now owns 612,646 shares of the company’s stock, valued at $9,024,275.58. The trade was a 1.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

David Krempa also recently made the following trade(s):

• On Friday, June 13th, David Krempa sold 6,800 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $14.77, for a total transaction of $100,436.00.
• On Thursday, June 12th, David Krempa sold 16,977 shares of Eton Pharmaceuticals stock. The shares were sold at an average price of $14.92, for a total transaction of $253,296.84.

Eton Pharmaceuticals Price Performance

Shares of NASDAQ ETON traded down $0.13 during mid-day trading on Monday, hitting $14.17. 324,095 shares of the company’s stock traded hands, compared to its average volume of 224,421. Eton Pharmaceuticals, Inc. has a 1 year low of $3.18 and a 1 year high of $21.48. The company’s 50-day moving average is $16.54 and its two-hundred day moving average is $15.05. The company has a market capitalization of $380.01 million, a P/E ratio of -64.41 and a beta of 1.28.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its quarterly earnings data on Tuesday, May 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.02). Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. The company had revenue of $17.28 million during the quarter, compared to the consensus estimate of $14.33 million. Equities analysts anticipate that Eton Pharmaceuticals, Inc. will post -0.14 EPS for the current fiscal year.

Institutional Investors Weigh In On Eton Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Nantahala Capital Management LLC increased its stake in Eton Pharmaceuticals by 5.1% in the first quarter. Nantahala Capital Management LLC now owns 1,175,951 shares of the company’s stock worth $15,264,000 after purchasing an additional 57,468 shares during the period. Mink Brook Asset Management LLC purchased a new position in shares of Eton Pharmaceuticals during the fourth quarter worth approximately $6,071,000. Acadian Asset Management LLC increased its holdings in Eton Pharmaceuticals by 61.9% during the 1st quarter. Acadian Asset Management LLC now owns 402,428 shares of the company’s stock worth $5,219,000 after purchasing an additional 153,923 shares during the period. Cannell Capital LLC bought a new stake in Eton Pharmaceuticals during the 4th quarter valued at $5,079,000. Finally, Millennium Management LLC raised its position in Eton Pharmaceuticals by 156.3% during the 1st quarter. Millennium Management LLC now owns 355,929 shares of the company’s stock valued at $4,620,000 after purchasing an additional 217,042 shares in the last quarter. Hedge funds and other institutional investors own 27.86% of the company’s stock.

Analyst Upgrades and Downgrades

ETON has been the topic of several research analyst reports. Craig Hallum boosted their price target on shares of Eton Pharmaceuticals from $26.00 to $28.00 and gave the stock a “buy” rating in a research note on Wednesday, May 14th. HC Wainwright reissued a “buy” rating and set a $35.00 price target (up from $33.00) on shares of Eton Pharmaceuticals in a research note on Thursday, May 29th. Finally, B. Riley reaffirmed a “buy” rating and issued a $26.00 price objective (up previously from $24.00) on shares of Eton Pharmaceuticals in a research note on Friday, May 16th.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.